The percentage of pSS patients with anti-SSA/Ro60 antibodies was significantly higher in the pSS-advanced ILD patients (ILA score 3) than in the pSS no-ILD subgroup (ILA score 0) (p < 0.01) (Table 1). This evidence concerns the gene RO60 and interstitial lung disease.